李宝力男 博士 副研究员 博士生导师

邮箱：libaolilibaoli@163.com

2018年6月博士毕业于华东理工大学药学院，同年8月赴美国墨菲特癌症研究中心从事博士后研究。于2021年通过高层次人才引进到海南大学药学院。

1. 教育背景

2018.09 — 2021.09：墨菲特癌症研究中心，药物开发部，博士后研究员；

2013.09 — 2018.06：华东理工大学，药学院，药学专业，博士（硕博连读）；

2009.09 — 2013.06：华东理工大学，药学院，药物制剂专业、英语专业，双学士。

2. 科研情况

主持国家自然科学基金青年基金一项，参与国家自然科学基金面上基金一项，参与美国Bankhead-Coley基金一项。以第一作者或通讯作者发表SCI论文9篇，申请并获授权发明专利3项。本人及团队所发现的抗MRSA候选新药JX08-2于2018年12月实现技术转化，转让合同金额为14000万。JX08-2的临床前研发已获得国家新药创制重大专项资助(2019ZX09721001-004-003)，预计2022年底提交临床试验申请。

3. 研究领域

药物分子设计、结构优化及作用机制研究

4. 科研项目

国家自然科学基金青年基金项目，靶向细菌毒力的抗耐药铜绿假单胞菌增敏剂研发及抗细菌毒力机制研究，2022.01-2024.12，24万，主持。

5．代表性论文 (†第一作者、并列第一作，*通讯作者)

1） Xinming Li, Donglei Shi, Yihe Song, Yixiang Xu, Ying Gao, Wenjing Qiu, Xin Chen, Xiaokang Li, Yunyuan Huang, Yanjun Feng, Baoli Li*, Yuan Guo*, Jian Li*, Specific tracking of monoamine oxidase A in HF models by a far-red fluorescent probe with an ultra large Stokes shift, Chinese Chemical Letters, 2021, accepted.

2） Ryan R Davis, Baoli Li, Sang Y Yun, Alice Chan, Pradeep Nareddy, Steven Gunawan, Muhammad Ayaz, Harshani R. Lawrence, Gary W. Reuther, Nicholas J. Lawrence, Ernst Schönbrunn*, Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof, Journal of Medicinal Chemistry, 2021, 64, 2228-2241.

3） Taotao Lu†, Xinyu Zheng†, Fei Mao, Qiao Cao, Qin Cao, Jin Zhu, Lefu Lan*, Baoli Li*, Jian Li*, Discovery of Novel Synergist Repurposes Polymyxin B as an Effective Antibacterial Agent against Clinical Polymyxin-resistant Pseudomonas aeruginosa DK2, Journal of Medicinal Chemistry, in revision.

4） Xiaokang Li†, Jian Lu†, Yixiang Xu†, Jiaying Wang, Xiaoxia Qiu, Lei Fan, Baoli Li, Wenwen Liu, Fei Mao, Jin Zhu, Xu Shen*, Jian Li*, Discovery of nitazoxanide-based derivatives as autophagy activators for the treatment of Alzheimer's disease, Acta Pharmaceutica Sinica B, 2020, 10, 646-666.

5） Shuaishuai Ni†, Xin Chen†, Qing Yu†, Yixiang Xu, Zhiguo Hu, Junqian Zhang, Wenjuan Zhang, Baoli Li, Xi Yang, Fei Mao, Jing Huang, Yi Sun, Jian Li*, Lijun Jia*, Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth, European Journal of Medicinal Chemistry, 2020, 185, 111848.

6） Shuaishuai Ni†, Baoli Li†, Yixiang Xu†, Fei Mao, Xiaokang Li, Lefu Lan, Jin Zhu, Jian Li*, Targeting virulence factors as an antimicrobial approach: Pigment inhibitors, Medicinal Research Reviews, 2020, 40, 293-338.

7） Hanwen Wei†, Fei Mao†, Shuaishuai Ni†, Feifei Chen, Baoli Li, Xiaoxia Qiu, Linghao, Hu, Manjiong Wang, Xinyu Zheng, Jin Zhu, Lefu Lan*, Jian Li*. Discovery of novel piperonyl derivatives as diapophytoene desaturase inhibitors for the treatment of methicillin-, vancomycin- and linezolid-resistant Staphylococcus aureus infections, European Journal of Medicinal Chemistry, 2018, 145, 235-251.

8） Shuaishuai Ni†, Baoli Li†, Feifei Chen†, Hanwen Wei, Fei Mao, Yifu Liu, Yixiang Xu, Xiaoxi Qiu, Xiaokang Li, Wenwen Liu, Linghao Hu, Dazheng Ling, Manjiong Wang, Xinyu Zheng, Jin Zhu*, Lefu Lan*, Jian Li*, Novel staphyloxanthin inhibitors with improved potency against multidrug resistant staphylococcus aureus, ACS Medicinal Chemistry Letter, 2018, 9, 233-237.

9） Baoli Li†, Shuaishuai Ni†, Fei Mao†, Feifei Chen, Yifu Liu, Hanwen Wei, Wenhua Chen, Jin Zhu, Lefu Lan*, Jian Li*, Novel terminal bipheny-based diapophytoene desaturases (CrtN) inhibitors as anti-MRSA/VISR/LRSA agents with reduced hERG activity, Journal of Medicinal Chemistry, 2018, 61, 224-250.

10） Baoli Li†, Shuaishuai Ni†, Feifei Chen, Fei Mao, Hanwen Wei, Yifu Liu, Jin Zhu, Lefu Lan*, Jian Li*, Discovery of potent benzocycloalkane derived diapophytoene desaturase (CrtN) inhibitors with enhanced safety profile for the treatment of MRSA, VISA and LRSA infection, ACS Infectious Disease, 2018, 4, 208-217.

11） Shuaishuai Ni†, Hanwen Wei†, Baoli Li†, Feifei Chen, Yifu Liu, Wenhua Chen, Yixiang Xu, Xiaoxia Qiu, Xiaokang Li, Yanli Lu, Wenwen Liu, Linhao Hu, Dazheng Lin, Manjiong Wang, Xinyu Zheng, Fei Mao, Jin Zhu, Lefu Lan*, Jian Li*, Novel inhibitors of staphyloxanthin virulence factor in comparison with linezolid and vancomycin versus methicillin-resistant, linezolid-resistant, and vancomycin-intermediate staphylococcus aureus infections in vivo, Journal of Medicinal Chemistry, 2017, 60, 8145-8159.

12） Sheng Ma†, Jing Deng†, Baoli Li†, Xiujiang Li, Zhaowei Yan, Jin Zhu, Gang Chen, Zhong Wang*, Hualiang Jiang, Liyan Miao*, Jian Li*. Development of second-generation small-molecule RhoA inhibitors with enhanced water solubility, tissue potency, and significant in vivo efficacy, ChemMedChem, 2015, 10, 193-206.

13） Baoli Li†, Fang Xiao*, Wenchao Lu, Yuyun Sun, Jin Zhu, Jian Li*, Discovery and synthesis of N2, N4-substitued-cycloalkyl [d] pyrimidine-2, 4-diamine analogs: The first examples of small-molecular FGFR-1, Chinese Chemical Letters, 2014, 25, 989-994.

6．已授权发明专利

1） 李剑、蓝乐夫、倪帅帅、陈菲菲、魏汉文、刘毅夫、李宝力、毛斐、朱进；苯并含氧脂肪环甲胺类化合物，2021年1月13日，中国，ZL201611073277.2.

2） Li, Jian; Lan, Lefu; Li, Baoli; Chen, Feifei; Ni, Shuaishuai; Liu, Yifu; Wei, Hanwen; Mao, Fei; Zhu, Jin. BENZOHETEROCYCLYL ALKYLAMINE COMPOUNDS AND USE THEREOF. 2020年11月10日, US, 10829464.

3） 李剑；蓝乐夫；李宝力；陈菲菲；倪帅帅；刘毅夫；魏汉文；毛斐；朱进；苯并杂环环烷基胺类化合物及其用途，2020年8月18日, 中国，ZL201611037724.9.

7．参加会议

1） Baoli Li, Sang Y. Yun, Ryan R. Davis, Narmin Amin, Gary W. Reuther, Ernst Schönbrunn, Harshani R. Lawrence, and Nicholas J. Lawrence. New Approaches to Target JAK2 for Myeloproliferative Neoplasms. Poster Presentation at Synth-Posium by the Sea 2021, May 2021.

2） Baoli Li, Sang Y. Yun, Ryan R. Davis, Narmin Amin, Gary W. Reuther, Ernst Schönbrunn, Harshani R. Lawrence, and Nicholas J. Lawrence. New Approaches to Target JAK2 for Myeloproliferative Neoplasms. Poster Presentation at Moffitt Scientific Symposium, April 2021.

3） Baoli Li, Sang Y. Yun, Ryan R. Davis, Pradeep R. Nareddy, Narmin Amin, Gary W. Reuther, Ernst Schönbrunn, Harshani R. Lawrence, and Nicholas J. Lawrence. Development of Potential PROTAC Degraders of JAK2: Design, Synthesis and SAR Studies. Oral Presentation at American Association for Cancer Research (AACR), June 2020.

欢迎具有药学、化学、生物学背景的同学报考本课题组研究生。